ALLMedicine™ Adenovirus Center

Nov 30th, 2022 - The molecular detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is key for clinical management and surveillance. Funded by the European Centre for Disease Prevention and Control, we conducted an external quality assessment ...

Nov 29th, 2022 - Oncolytic viruses (OVs) exert their antitumor effect through selective killing of cancer cells and induction of host anti-tumor immunity. This review aims to summarize the recent and current trials with OVs for the treatment of lung cancer. Severa...

Nov 28th, 2022 - Pancreatic ductal adenocarcinoma (PDAC) is often refractory to treatment with gemcitabine (GEM) and immune checkpoint inhibitors including anti-programmed cell death ligand 1 (PD-L1) antibody. However, the precise relationship between GEM-resistan...

Nov 28th, 2022 - To evaluate the clinical features, treatment, and visual outcome of patients with acute retinal necrosis (ARN). The data of patients were retrospectively reviewed. Factors associated with visual loss and factors affecting the risk for retinal deta...

Nov 28th, 2022 - Adenovirus nephritis (ADVN) is a rare and understudied complication of kidney transplantation. Unlike BK virus nephropathy (BKVN), our knowledge of clinicopathologic manifestations of ADVN remains rudimentary and essentially limited to case report...

Sep 30th, 2016 - Community acquired viruses (CRVs) may cause severe disease in cancer patients. Thus, efforts should be made to diagnose CRV rapidly and manage CRV infections accordingly. A panel of 18 clinicians from the Infectious Diseases Working Party of the G...

Oct 14th, 2022 - This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, single dose study to determine the safety of valoctocogene roxaparvovec (an Adenovirus-Associated Virus (AAV) based gene therapy vector) in severe Hemophilia A patient...

Oct 14th, 2022 - Background: Study subjects exposed to gene therapy interventions may be at risk for delayed or longterm adverse consequences. The U.S. Food and Drug Administration (FDA) has issued Long Term Follow-up After Administration of Human Gene Therapy Pro...

Oct 14th, 2022 - This study is being conducted to assess the safety and immunogenicity of the Ad26.ZEBOV (Dose 1), MVA-BN-Filo (Dose 2) vaccine regimen, administered with a 56-day interval between the two doses, in adults and children previously enrolled in the co...

Oct 14th, 2022 - This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy vector in particip...

Oct 12th, 2022 - This is a phase 1, dose-escalating study to evaluate the safety and immunogenicity of a single dose of either Ad5-triCoV/Mac, a replication deficient human adenovirus vector, or ChAd-triCoV/Mac, a replication deficient chimpanzee adenovirus 68 vec...

Nov 23rd, 2022 - They call me and I go. – William Carlos Williams I never get sick. I've never had the flu. When everyone's got a cold, I'm somehow immune. The last time I threw up was June 29th, 1980. You see, I work out almost daily, eat vegan, and sleep plenty....

Oct 18th, 2022 - ANAHEIM — A wide range of factors can cause myocarditis; most often viral infections cause myocarditis in children and teens, according to Ryan Butts, MD, medical director of the pediatric advanced cardiac care program at the University of Texas S...

Sep 16th, 2022 - The European Medicines Agency (EMA) Committee for Orphan Medical Products has granted an orphan drug designation (ODD) to CAN-2409 for the treatment of patients with glioma, according to an announcement from Candel Therapeutics.1 CAN-2409 is a ...

Sep 7th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. China and India have approved COVID-19 vaccines that can be given through the nose or mouth, which scientists hope will be a "game changer" for th...

Sep 6th, 2022 - HONG KONG (Reuters) - China's CanSino Biologics Inc said on Sunday that its recently developed COVID-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business. The inhaled vers...